(Q34379366)

1 August 2017

RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo (English)

1 reference

1 August 2017

Urban-Klein B

1

1 reference

1 August 2017

Werth S

2

1 reference

1 August 2017

Abuharbeid S

3

1 reference

1 August 2017

Czubayko F

4

1 reference

1 August 2017

Aigner A

5

1 reference

1 August 2017

1 March 2005

1 reference

1 August 2017

1 reference

1 August 2017

12

1 reference

1 August 2017

461-466

1 reference

1 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302425

1 August 2017

0 references

cites work

Single-stranded antisense siRNAs guide target RNA cleavage in RNAi

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

siRNA-mediated gene silencing in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Inhibition of hepatitis B virus in mice by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Modulation of HIV-1 replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Interference of hepatitis C virus RNA replication by short interfering RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

A system for stable expression of short interfering RNAs in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Gene transfer with modified polyethylenimines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Targeted nucleic acid delivery into tumors: new avenues for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Linear Polyethylenimine as a Tool for Comparative Studies of Antisense and Short Double-Stranded RNA Oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Effective polyethylenimine-mediated gene transfer into human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

7 January 2021

ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

7 January 2021

RNA interference targeting Fas protects mice from fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

7 January 2021

Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

7 January 2021

An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302425

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302425

1 reference

1 August 2017

1 reference